EUCTR2015-005663-17-FR进行中（未招募）1 期
A Long-term Follow-up Study for Cardiac Safety in the Patients with HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 573
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Subjects must meet all of the following criteria to be eligible for the study:
- •1.Subjects who have completed the study treatment of SB3-G31-BC according to the protocol.
- •2.Subjects must provide informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 516
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 57
排除标准
- •Subjects unwilling to follow the study requirements are not eligible for the study.
研究者
相似试验
进行中（未招募）
1 期
ong-term Follow-up Study for Cardiac Safety in the Patients with Breast Cancer Who Have Completed the Main StudySubjects with primary HER2 positive early or locally advanced breast cancer, who received the IP (SB3 or Herceptin®) in the SB3-G31-BCtrial.MedDRA version: 21.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005663-17-PLSamsung Bioepis Co., Ltd.612
进行中（未招募）
1 期
ong-term Follow-up Study for Cardiac Safety in the Patients with Breast Cancer Who Have Completed the Main StudySubjects with primary HER2 positive early or locally advanced breast cancer, who have completed the study treatment of SB3-G31-BC.MedDRA version: 18.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005663-17-CZSamsung Bioepis Co., Ltd.573
进行中（未招募）
1 期
ong-term Follow-up Study for Cardiac Safety in the Patients with Breast Cancer Who Have Completed the Main StudySubjects with primary HER2 positive early or locally advanced breast cancer, who have completed the study treatment of SB3-G31-BC.MedDRA version: 23.0Level: PTClassification code 10065430Term: HER2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005663-17-ROSamsung Bioepis Co., Ltd.538
进行中（未招募）
1 期
ong-term Follow-up Study for Cardiac Safety in the Patients with Breast Cancer Who Have Completed the Main StudySubjects with primary HER2 positive early or locally advanced breast cancer, who received the IP (SB3 or Herceptin®) in the SB3-G31-BC trial.MedDRA version: 21.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005663-17-BGSamsung Bioepis Co., Ltd.612
尚未招募
3 期
A Long-term Follow-up Study for Cardiac Safety in the Patients with HER2 positive Breast Cancer Who Have Completed the SB3-G31-BC study.CTRI/2020/02/023210Samsung Bioepis Co Ltd